Novavax, Inc. (NASDAQ:NVAX) Shares Tumbled on Wednesday Following Clinical Hold on Flu Combination Vaccine
Highlights,Novavax faces a clinical hold following the report of motor neuropathy in a trial participant nearly two years post-vaccination.,Analysts at Jefferies revised their price target for Novavax from $31 to $25 amid increased uncertainty about the